Targeted Therapies for Stomach Cancer

Targeted drugs may work in some cases when standard chemo drugs don’t. They also tend to have different side effects from standard chemo drugs. 

Chemotherapy (chemo) drugs target cells that divide rapidly, which is why they often work against cancer cells. But there are other aspects of cancer cells that make them different from normal cells. In recent years, researchers have developed new drugs to try to target these differences. 


About 1 out of 5 of stomach cancers has too much of a growth-promoting protein called HER2 on the surface of the cancer cells. Tumors with increased levels of HER2 are called HER2-positive.

Trastuzumab (Herceptin) is a monoclonal antibody, a man-made version of a very specific immune system protein, which targets the HER2 protein. Giving trastuzumab with chemo can help some patients with advanced, HER2-positive stomach cancer live longer than giving chemo alone.

This drug only works if the cancer cells have too much HER2, so samples of your tumor must be tested to look for HER2 before starting treatment (see Tests for Stomach Cancer). It is not used in people whose cancer is HER2-negative.

Trastuzumab is injected into a vein (IV). For stomach cancer, it is given once every 2 or 3 weeks along with chemo. The best length of time to give it is not yet known.

The side effects of trastuzumab tend to be relatively mild. They can include fever and chills, weakness, nausea, vomiting, cough, diarrhea, and headache. These side effects occur less often after the first dose. This drug can also rarely lead to heart damage. The risk of heart damage is increased if trastuzumab is given with certain chemo drugs called anthracyclines, such as epirubicin (Ellence) or doxorubicin (Adriamycin).


For cancers to grow and spread, they need to create new blood vessels so that the tumors get blood and nutrients. One of the proteins that tells the body to make new blood vessels is called VEGF. VEGF binds to cell surface proteins called receptors to act. Ramucirumab (Cyramza®) is a monoclonal antibody that binds to a receptor for VEGF. This keeps VEGF from binding to the receptor and signaling the body to make more blood vessels. This can help slow or stop the growth and spread of cancer.

Ramucirumab is used to treat advanced stomach cancer, most often after another drug stops working.

This drug is given as infusion into a vein (IV) every 2 weeks.

The most common side effects of this drug are high blood pressure, headache, and diarrhea. Rare but possibly serious side effects include blood clots, severe bleeding, holes forming in the stomach or intestines (perforations), and problems with wound healing. If a hole forms in the stomach or intestine it can lead to severe infection and may require surgery to correct.

Other targeted drugs

Other targeted therapy drugs are being tested against stomach cancer. Some of these also focus on the HER2 protein, while others have different targets. Some of these drugs are discussed in more detail in What’s New in Stomach Cancer Research?

You can read more in Targeted Therapy.

The American Cancer Society medical and editorial content team

Our team is made up of doctors and oncology certified nurses with deep knowledge of cancer care as well as journalists, editors, and translators with extensive experience in medical writing.

Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): A phase 3, open-label, randomized controlled trial. Lancet. 2010;376:687−697.

Fuchs CS, Tomasek J, Yong CJ, et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2014 Jan 4;383(9911):31-9. Epub 2013 Oct 3.

Muro K, Boku N, Yamada Y et al. Multicenter phase II study of RAD001 for previously treated metastatic gastric cancer:
Preliminary results. J Clin Oncol. 2008;26 (May 20 suppl; abstr 4541).

National Cancer Institute. Physician Data Query (PDQ). Gastric Cancer Treatment. 2/2/2017. Accessed at: on November 20, 2017.

National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Gastric Cancer. v.3.2017. Accessed at on November 20, 2017.

Song H, Zhu J, Lu D. Molecular-targeted first-line therapy for advanced gastric cancer. Cochrane Database of Systematic Reviews. 2016;7. Art. No.: CD011461. DOI: 10.1002/14651858.CD011461.pub2.

Wong H, Yau T. Targeted therapy in the management of advanced gastric cancer: Are we making progress in the era of personalized medicine? Oncologist. 2012;17:346–358.

Last Revised: December 15, 2017

American Cancer Society medical information is copyrighted material. For reprint requests, please see our Content Usage Policy.